Duke's Ralph Snyderman, M.D. Joins SenGenix as Senior Medical Advisor and Board Member
DURHAM, N.C., Nov. 12, 2012 /PRNewswire-iReach/ -- SenGenix, a private medical diagnostics company developing protein-based sensor technology for point-of-care testing, announced today that Ralph Snyderman, MD, Chancellor Emeritus of Duke University, has joined the company and will serve as senior medical advisor and a member of the Board of Directors.
Snyderman served as Chancellor for Health Affairs at Duke for 15 years and guided development of the Duke University Health System, one of the first fully integrated academic health systems in the United States. He also served as its Chief Executive Officer. Prior to Duke, Snyderman was Senior Vice President, medical research and development, for Genentech. He has earned numerous honors and awards during his career and has served as an advisor and board member for several companies.
"Dr. Snyderman's experience in clinical medicine, biotechnology research and industry is an exceptional asset for SenGenix in commercializing its protein engineering technologies for fast, highly accurate and low cost point-of care testing," said Lawrence Cohen, Chief Executive Officer of SenGenix. "Dr. Snyderman's global reputation as a health system executive, clinician and researcher will help SenGenix build strong relationships with clinical investigators, physicians and hospital executives as we move forward in product development and into global market introduction."
Founded in 2012, SenGenix will commercialize protein engineering technologies to create a new platform for a menu of the most commonly ordered patient tests that can be performed in any environment -- emergency departments, operating rooms, out-patient surgical centers, physician offices, ambulances, and disaster sites. SenGenix's technology, which was originally developed at Duke University Medical Center, uses fluorescently responsive sensors printed on test strips to provide easy, highly accurate results in seconds with just a drop of blood. Unlike other point-of-care testing systems, no expensive sampling cartridges or reader instruments are required with SenGenix technology.
More information about SenGenix is available at www.sengenix.com.
Media Contact: Lawrence Cohen SenGenix, Inc., 646-354-8361, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE SenGenix, Inc.